The use of immunosuppressants of PD-1 and CTLA-4 to treat malignant tumors has also been successful in a variety of tumors, but the efficacy in gliomas has been unsatisfactory. Therefore, the TIDE score was selected to assess the efficacy of PD1 and CTLA4 immunotherapy in the two risk groups. Our results show that the high-risk patients may respond well to immune checkpoint therapy (PD-1, CTLA4) and benefit from immunotherapy. This evidence concerns the gene PDCD1 and glioma.